The pitch for gene therapy in Alzheimer's has always been seductively simple: one injection, a hollowed-out virus carrying a corrective instruction, and a brain that keeps making its own medicine for years afterwards. It is the kind of sentence that makes a family sit forward at a clinic appointment. A review published on 15 September 2026 in Frontiers in Aging Neuroscience spends its length quietly dismantling the simplicity of it, and what it finds standing in the way is less glamorous than biology. It is arithmetic, geography and quality control: how much vector, reaching which cells in which regions, in a product that can be manufactured identically batch after batch.

First, what this paper is and is not. It is a narrative review, a survey of published work rather than a new experiment or a trial. The authors, writing from institutions including the School of Traditional Chinese and Western Medicine at Gansu University of Chinese Medicine in Lanzhou, searched PubMed, the Web of Science Core Collection and ClinicalTrials.gov in July 2026, then followed citations to reconcile what they found. No new patients were treated, no results were pooled into a single statistic. Its contribution is a way of grading evidence, not a fresh piece of it.

That grading system is the interesting part. The review insists on separating vector performance (can the virus get in and keep expressing?) from payload-specific biology (does the gene it carries actually do anything useful?), and then scores delivery and biodistribution, molecular target engagement, pathological modification, functional outcomes, safety and clinical efficacy as separate domains rather than letting a strong result in one stand in for the rest. Its central claim is that translational readiness should be judged by biological fit and evidence maturity, not by transduction efficiency or expression durability alone. The strategies it surveys are the familiar map of Alzheimer's research rendered in viral vectors: approaches aimed at amyloid production and clearance, at tau expression and degradation, at the brain's immune microenvironment, at genetic risk, and at neurotrophic support.

Then comes the unglamorous section that gives this story its spine. A clinically credible programme, the review argues, needs comparability across research-grade, toxicology-grade and clinical-grade material, reproducible potency assays and critical quality attributes defined in advance, with release specifications covering product identity, genome integrity, capsid composition, purity and potency. These demands get harder, not easier, as ambition grows: the wider the area of brain a therapy tries to cover, the more vector is required, and the review notes that manufacturing burden and per-dose cost rise with it. Its blunt practical conclusion is that candidates should be chosen for manufacturability alongside biological activity, human-relevant biodistribution and safety, rather than simply picking whichever vector lights up the most mouse brain. Its closing list of priorities reads like a to-do note pinned above a lab bench: quantitative dose-coverage relationships, human-relevant and nonhuman-primate validation, payload-specific safety, biomarker-defined patient selection, reproducible manufacturing, long-term clinical surveillance. Non-viral and bio-nano delivery systems get a mention as a future research direction, explicitly not as an established therapy.

Set that against how thin the human record still is. The most advanced Alzheimer's-specific example the field can point to is LX1001, an AAVrh.10 vector delivering the protective APOE2 gene, tested in an open-label phase 1/2 dose-escalation trial (NCT03634007) in people who carry two copies of APOE4. Topline results reported as a conference abstract in Alzheimer's and Dementia in December 2025 describe 15 participants dosed across four ascending single-dose cohorts, the vector given into the cerebrospinal fluid at the craniocervical junction, with 12 months of follow-up available for the first three cohorts and six months for the fourth. Treatment was described as generally safe and well tolerated, with no amyloid-related imaging abnormalities, and APOE2 appeared in the cerebrospinal fluid of every participant in a dose-dependent way. These are preliminary, early-phase findings in 15 people with no control group, and dose-dependent protein expression is a signal that the delivery worked, not evidence that anyone's memory was protected.

For a family, the honest translation is that the bottleneck has moved somewhere unromantic, and that is arguably good news. The questions now being asked are answerable ones: how far does the vector spread, at what dose, in a primate brain closer in size to ours, and can the same batch be made again next year to the same specification? None of that produces a treatment this year. All of it is what would have to be settled before one could exist.